Hemolytic anemia screening: Difference between revisions
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) |
||
| Line 9: | Line 9: | ||
==Screening== | ==Screening== | ||
In some cases, screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency can be done to determine if a patient is at risk for hemolytic anemia. Primaquine, sulfa drugs, and fava beans can trigger hemolytic crises in the setting of G6PD deficiency.<ref name="pmid24372186">{{cite journal| author=Luzzatto L, Seneca E| title=G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. | journal=Br J Haematol | year= 2014 | volume= 164 | issue= 4 | pages= 469-80 | pmid=24372186 | doi=10.1111/bjh.12665 | pmc=4153881 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24372186 }} </ref> Rasburicase has also been shown to trigger hemolytic episodes, so G6PD screening is important prior to administration of rasburicase.<ref name="pmid24372186">{{cite journal| author=Luzzatto L, Seneca E| title=G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. | journal=Br J Haematol | year= 2014 | volume= 164 | issue= 4 | pages= 469-80 | pmid=24372186 | doi=10.1111/bjh.12665 | pmc=4153881 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24372186 }} </ref> | In some cases, screening for [[glucose-6-phosphate dehydrogenase]] (G6PD) deficiency can be done to determine if a patient is at risk for hemolytic anemia. Primaquine, sulfa drugs, and fava beans can trigger hemolytic crises in the setting of G6PD deficiency.<ref name="pmid24372186">{{cite journal| author=Luzzatto L, Seneca E| title=G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. | journal=Br J Haematol | year= 2014 | volume= 164 | issue= 4 | pages= 469-80 | pmid=24372186 | doi=10.1111/bjh.12665 | pmc=4153881 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24372186 }} </ref> Rasburicase has also been shown to trigger hemolytic episodes, so G6PD screening is important prior to administration of rasburicase.<ref name="pmid24372186">{{cite journal| author=Luzzatto L, Seneca E| title=G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. | journal=Br J Haematol | year= 2014 | volume= 164 | issue= 4 | pages= 469-80 | pmid=24372186 | doi=10.1111/bjh.12665 | pmc=4153881 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24372186 }} </ref> | ||
==References== | ==References== | ||
Revision as of 02:07, 27 October 2017
|
Hemolytic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemolytic anemia screening On the Web |
|
American Roentgen Ray Society Images of Hemolytic anemia screening |
|
Risk calculators and risk factors for Hemolytic anemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
There is no major role for screening for hemolytic anemia. In some cases, testing for G6PD deficiency can be done if a patient will be receiving medications that are known to preciptate oxidative stress.
Screening
In some cases, screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency can be done to determine if a patient is at risk for hemolytic anemia. Primaquine, sulfa drugs, and fava beans can trigger hemolytic crises in the setting of G6PD deficiency.[1] Rasburicase has also been shown to trigger hemolytic episodes, so G6PD screening is important prior to administration of rasburicase.[1]
References
- ↑ 1.0 1.1 Luzzatto L, Seneca E (2014). "G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications". Br J Haematol. 164 (4): 469–80. doi:10.1111/bjh.12665. PMC 4153881. PMID 24372186.